Neurocrine Biosciences
NBIX
#1482
Rank
NZ$19.31 B
Marketcap
$191.30
Share price
-1.75%
Change (1 day)
-0.78%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2023 (TTM): $3.20

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is $3.17. In 2022 the company made an earnings per share (EPS) of $2.60 an increase over its 2021 EPS that were of $1.54.

EPS history for Neurocrine Biosciences from 1997 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$3.2023.09%
2022$2.6069.47%
2021$1.54-78.21%
2020$7.05990%
2019$0.6581.82%
2018$0.36-113.5%
2017-$2.630.62%
2016-$2.6257.28%
2015-$1.6625.61%
2014-$1.3318.84%
2013-$1.12-1085.71%
2012$0.11-89.71%
2011$1.10-500%
2010-$0.27-86.92%
2009-$2.10-43.48%
2008-$3.72-57.8%
2007-$8.8192.58%
2006-$4.57371.67%
2005-$0.97-52.76%
2004-$2.0536.56%
2003-$1.50-70%
2002-$5.01118.31%
2001-$2.308.4%
2000-$2.1248.86%
1999-$1.42-20%
1998-$1.78-479.31%
1997$0.47

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$3.38 6.63%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.89-71.94%๐Ÿ‡ฌ๐Ÿ‡ง UK
-$4.78-251.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$8.78 177.00%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.95 87.79%๐Ÿ‡บ๐Ÿ‡ธ USA
$3.01-5.10%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.76-123.98%๐Ÿ‡บ๐Ÿ‡ธ USA
-$4.90-254.59%๐Ÿ‡บ๐Ÿ‡ธ USA